Support for third-party writing assistance for this abstract, furnished by Alison McGonagle, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd., Basel, Switzerland. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. Curr Allergy Asthma Rep. 2023 Jan;23(1):1-11. doi: 10.1007/s11882-022-01052-z. A. This site needs JavaScript to work properly. Bayer to Highlight New Research at ESMO 2017 Congress - PR Newswire The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. and transmitted securely. Carboplatin induces DNA double strand breaks, which are repaired by BRCA recombination repair enzymes. *Correspondence: Wen-Fang Cheng, wenfangcheng@yahoo.com, Creative Commons Attribution License (CC BY). Curr Pharm Des. Utilizing Biologics in Drug Desensitization. Cancer 109, 10721078. J. Med. These ESMO Clinical Practice Guidelines provide recommendations on the prevention/management of dermatological toxicities. (2005) reported that all carboplatin-associated hypersensitivity reactions occur in patients with prior carboplatin exposure, and Tamiya et al. Oncol. A total of 59 women experienced mild signs and symptoms (grades 1 and 2), including skin rash (69.3%), skin itching (64.0%), facial flushing (56.0%), dyspnea (41.3%), chest pain (25.3%), tachycardia (18.7%), paresthesias (16.0%), abdominal cramping (13.3%), and diaphoresis (12.0%). Paclitaxel plus platinum-based chemotherapy vs. conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. doi: 10.1111/j.1048-891x.2005.14401.x, Takase, N., Matsumoto, K., Onoe, T., Kitao, A., Tanioka, M., Kikukawa, Y., et al. Therefore, disease severity, histological type, malignant ascites, past drug allergies, and cumulative carboplatin dose are risk factors for carboplatin-related hypersensitivity reactions. de Las Vecillas Snchez L, Alenazy LA, Garcia-Neuer M, Castells MC. News, highlights and insights download your copy here. EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes. 57 . Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. National Library of Medicine Close monitoring is warranted for patients with any one of these three risk factors who are receiving carboplatin. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. The comparison between other countries and ours about characteristics of the patients receiving carboplatin-based chemotherapy and risk factors of carboplatin-related hypersensitivity reactions. 21, 31943200. MBC: CLEOPATRA (NCT00567190; PMID 22149875, 23602601, 25693012; 32171426), MetaPHER (NCT02402712; 33748921); EBC: APHINITY (NCT01358877; 28581356, 33539215), NeoSphere (NCT00545688; 22153890, 27179402), TRYPHAENA (NCT00976989; 23704196, 29223479), BERENICE (NCT02132949; 29253081, SABCS 2017 P5-20-04), FeDeriCa (NCT03493854; 33357420), PHranceSCa (NCT03674112; ESMO 2020 165MO). Disclaimer. In the late 1980s, more than a dozen phase I studies analyzed the efficacy of paclitaxel as a single agent. However, prolonged carboplatin use is associated with an increased incidence of carboplatin-related hypersensitivity reactions (Markman et al., 1999; Wang et al., 2009). The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. (2003). This study was approved by the Research Ethics Committee at the National Taiwan University Hospital (201706023RINC). doi: 10.1111/IGC.0b013e3181a1bf2e, Ledermann, J. Cancer. Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer. This Webinar series brings together all the relevant stakeholders who are developing each guideline, as well as those who are consulting and implementing the guideline. Characteristics of the 735 women receiving carboplatin-based chemotherapy. LBA10004 The full, final text of this abstract will be available at abstracts.asco.org at 2:00 PM (EDT) on Friday, June 2, 2017, and in the Annual Meeting Proceedings online supplement to the June . Our results revealed carboplatin-related hypersensitivity reactions in 1 out of 10 women treated with a carboplatin-containing regimen for ovarian, fallopian tube, or primary peritoneal cancer. (2010). A spotlight on alkaloid nanoformulations for the treatment of lung cancer. 20, 566573. 24, 2432. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. -. Pharmacol. The results of the trial could answer whether carboplatin hypersensitivity patients have similar chemo-responses in non-platinum regimens without compromising the efficacy of the antineoplastic regimens of these patients. This site uses cookies. ESMO Clinical Practice Guidelines: Supportive and Palliative Care, ESMO Clinical Practice Guidelines on Palliative Care: Advanced Care Planning, Clinical Practice Guideline Anxiety and Depression, Anaemia and Iron Deficiency in Patients With Cancer, Clinical Practice Guidelines Management of Anaemia and Iron deficiency, Clinical Practice Guidelines Bone Health in Cancer Patients, Clinical Practice Guidelines Cancer Cachexia in Adult Patients, Clinical Practice Guidelines Management of cancer pain, Clinical Practice Guidelines - Cancer-related Fatigue, Clinical Practice Guidelines Care at the End of Life, Central Venous Access in Oncology: ESMO Clinical Practice Guidelines, Management of Chemotherapy Extravasation: ESMO Clinical Practice Guidelines, Clinical Practice Guidelines Constipation in advanced cancer, Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Real World Data and Digital Health Working Group, Translational Research and Precision Medicine Working Group, ESMO-Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group, ESMO-MCBS Working Group: Open Call for New Extended Members, ESMO Co-Editors-in-Chief for ESMO Journals Open Call for Members, ESMO Clinical Research Observatory Task Force (ECRO), Notification of 2022 ESMO General Assembly Vote, EnLiST ESMO Adaptation of Line of Systemic Therapy, Cancer Patient Management During the COVID-19 Pandemic, Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO Courses on Medical Oncology for Medical Students, External Oncology Fellowship Opportunities, ESMO Resilience Task Force: Survey Series, ESMO-MORA Recertification Process and Requirements, ESMO Certificate of Professional Development, Professor of Cancer Research and Tony Charlton Chair, Monash University, Melbourne, Australia, Acknowledgements: Rationalizing Bureaucracy, Bibliography on Clinical Trial Procedures, ESMO Designated Centres of Integrated Oncology & Palliative Care, Palliative and Supportive Care Sessions at ESMO Congress 2022 Paris, Krebstherapie whrend der COVID-19-Pandemie, Traitement du Cancer au Cours de la Pandmie de COVID-19, Le Cure per il Cancro Durante la Pandemia da COVID-19, Cuidado del cncer durante la pandemia de COVID-19, Access to Cancer Medicines and Technologies, ESMOs Mission on Access to Cancer Medicines and Technologies, ESMO Public Policy Track and Special Sessions. Would you like email updates of new search results? eCollection 2022 Apr. Care. Clinical features of hypersensitivity reactions to carboplatin. With a lower carboplatin infusion rate and pre-treatment with anti-allergy drugs, all of these patients were able to tolerate re-treatment with carboplatin, although 48 (78.7%) of these 61 patients developed hypersensitivity again despite the desensitization protocol. Open. A sincere thanks to the almost 24,000 participants who attended this year's annual congress! These differences were likely related to the fact that patients with advanced disease, serous carcinoma, and ascetic malignant cells required significantly more carboplatin treatment cycles and higher carboplatin doses. Clinical analysis of thirteen cases of hypersensitivity reactions to carboplatin. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., Sessa, C., et al. Prior to an infusion of a mAb, nurses should do the following (Olsen et al., 2019): . The incidence of carboplatin-related hypersensitivity was higher in patients with advanced stage disease (P < 0.001, Kruskal-Wallis test), serous and mixed histological types (P = 0.003, Kruskal-Wallis test), malignant ascites (P = 0.009, chi-square test), and history of other drug allergy (P < 0.001, chi-square test). The term 'hypersensitivity' should be used to describe objectively reprodu- cible symptoms or signs initiated by exposure to a dened stimu- lus at a dose tolerated by normal persons. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). doi: 10.1016/S0140-6736(03)13718-X, Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., et al. Similarly, Kandel et al. The ESMO Clinical Practice Guidelines, prepared and reviewed by leading experts and based on the findings of evidence-based medicine, provide you with a set of recommendations to help patients with the best care options. Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. Several methods have been developed to prevent carboplatin-related hypersensitivity reactions (Libra et al., 2003; Confino-Cohen et al., 2005; Gomez et al., 2009; Greene et al., 2010; Takase et al., 2015; Shah et al., 2016). European Hematology Association (EHA) and European . Lancet 361, 20992106. All funding for this site is provided directly by ESMO. Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. Life expectancy for cancer patients allergic and desensitized to carboplatin and non-allergic to carboplatin [from Sloane et al. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). doi: 10.1007/s00520-011-1123-y, Gomez, R., Harter, P., Lck, H. J., Traut, A., Kommoss, S., Kandel, M., et al. Gynecol. Oncology 61, 129133. The cumulative incidence of carboplatin-related hypersensitivity reactions increased with the number of carboplatin cycles (Figure 1A) and increasing dose (Figure 1B), especially at >8 cycles or a dose >3,500 mg. The annual ESMO Congress is the most prestigious and influential oncology platform in Europe and is the ideal place to learn about the latest science, network with colleagues and keep pace with today's rapid developments in cancer research. Br. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. J. Gynecol. Gerber, C. van den Hurk, P. Fernndez-Peas, D. Santini, F. Jahn, K. Jordan on behalf of the ESMO Guidelines Committee These ESMO Clinical Practice Guidelines provide recommendations on the . (2006). 53, 121122. WHIPPANY, N.J., Sept. 1, 2017 /PRNewswire/ -- Bayer will present the latest research from across its growing oncology portfolio at the European Society for Medical Oncology (ESMO) 2017 Congress . 4 - 9 Without premedication, hypersensitivity reactions (HSRs) occurred in 25%-30% of patients in these studies and clinical development of paclitaxel was consequently delayed. Monitor. Our present findings confirmed these factors and identified other risk factors, including advanced disease, serous histology, and the presence of malignant ascites. Symptoms and signs of hypersensitivity reactions amendable to desensitization. 18, 615620. The independent sample t-test was used to evaluate how carboplatin cycle and dose correlated with the incidence of hypersensitivity and severe hypersensitivity reactions. 4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. HHS Vulnerability Disclosure, Help Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. official website and that any information you provide is encrypted MeSH 84, 378382. There was a striking difference in PFSmedian 16.8 versus 5.6 months, HR 0.52 (highly significant)with the difference in PFS sustained at 12- and 18-month landmarks. Cancer 19, 12841287. Chan. (2009). It didn't disappoint. Previous data indicated that prior carboplatin exposure is the primary risk factor for carboplatin-related hypersensitivity reactions among all patients (Navo et al., 2006; Koshiba et al., 2009). Thus, the risk of severe carboplatin-related hypersensitivity may influence its usage in gynecological cancers, and it is important to develop protocols to reduce this risk, especially the risk of severe reactions. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. doi: 10.1007/s00280-009-1159-6, Iwamoto, T., Hirai, H., Yamaguchi, N., Kobayashi, N., Sugimoto, H., and Tabata, T. (2014). Author Mariana Castells 1 Affiliation 1 Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. J. Gynecol. Epub 2011 Jan 26. Bethesda, MD 20894, Web Policies eCollection 2022. Int. J Exp Clin Cancer Res (2011) 30:93.10.1186/1756-9966-30-93 Ann. Necessary cookies enable core functionality. The MASCC/ESMO guidelines recommend that patients receiving HEC are given a dose of 20 mg dexamethasone on Day 1 to prevent acute emesis; however, if the NK 1 RAs aprepitant or netupitant are also used, a reduced dose of 12 mg dexamethasone is recommended. The left side, Putative mechanism of protection against, Putative mechanism of protection against anaphylaxis during human desensitizations. Platinum-based combination chemotherapy is the recommended treatment for platinum-sensitive recurrent ovarian cancer (Parmar et al., 2003; Pfisterer et al., 2006; Pujade-Lauraine et al., 2010). We invite ESMO members and event attendees to view the 2017 webcasts and presentations using the link below. Analysis included treatment cycle, causative drug, severity of reaction as per CTCAE v4 . 10.1016/annonc/annonc687, Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC), Targeted Therapies and Precision Oncology, Interpreting Oncological Study Publications, Cancer Diagnosis and Treatment Evaluation, Cancer Treatment in Special Clinical Situations, Clinical Pharmacology of Anti-Cancer Agents, Controversies in upper GI oncology: ESMO Open Podcasts, International Prognostic Index Tools for Lymphoma, Anti-Cancer Agents and Biological Therapy, Drug-Drug Interactions with Kinase Inhibitors, PARP inhibition and DNA Damage Response (DDR), Cancer Aetiology, Epidemiology and Prevention, Cancer in Special situations (pregnancy, young, elderly, hereditary), Multikinase Inhibitor-Related Skin Toxicity, Precision Medicine and Validated Biomarkers, ESMO Recommendations in Precision Medicine. Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions. Furthermore, patients with carboplatin hypersensitivity had a higher incidence of previous allergic history to other cytotoxic drugs, including gemcitabine, paclitaxel, and doxorubicin, compared to those without (12/75 vs. 30/660, P < 0.001, chi-squared test; Table 7). are hypersensitivity reactions that are systemic and can be life-threatening (Olsen et al., 2019; Rosell et al., 2017). Gerber, C. van den Hurk, P. Fernndez-Peas, D. Santini, F. Jahn, K. Jordanon behalf of the ESMO Guidelines Committee. Multivariate analyses of clinical parameters for carboplatin-related hypersensitivity reactions. However, other studies have reported severe hypersensitivity reactions to cisplatin in patients with prior carboplatin hypersensitivity reactions (Zweizig et al., 1994; Dizon et al., 2002). Ke. (2005). Lacouture, V. Sibaud, P.A. These scores have been defined by the guideline authors and validated by the ESMO Translational Research and Precision Medicine Working Group.17 g Selpercatinib is EMA approved for treating adults with advanced or metastatic RET fusion-positive TC who had already received lenvatinib or sorafenib. The tests were analyzed at an accredited lab according to protocol. Hypersensitivity reactions associated with platinum-containing antineoplastic agents for thoracic malignancies. Abe et al. The cumulative incidence of carboplatin-related hypersensitivity was 2% at >3,500 mg, 6% at >7,500 mg, 8% at >10,000 mg, and 10% at >16,000 mg with a plateau beyond this dose (Figure 1B). There is evidence that inhibitory mechanisms blocking IgE/antigen mast cell activation are active during desensitization, enhancing safety. 28, 33233329. Necessary cookies enable core functionality. We retrospectively recruited all women with pathologically documented ovarian, fallopian tube, or primary peritoneal cancer treated with single-agent carboplatin or a carboplatin-based combination chemotherapy regimen at National Taiwan University Hospital from January 2006 to December 2013. Swain: Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Daiichi Sankyo; Financial Interests, Personal, Advisory Role: F. Hoffmann-La Roche Ltd./Genentech, Inc.; Financial Interests, Personal, Advisory Role: Exact Sciences (Genomic Health); Financial Interests, Personal, Advisory Role: Molecular Templates; Financial Interests, Personal, Advisory Role: Silverback Therapeutics; Financial Interests, Personal, Advisory Role: Tocagen; Financial Interests, Personal, Advisory Role: Lilly; Financial Interests, Personal, Advisory Role: Natera; Financial Interests, Personal, Advisory Role: Beijing Medical Foundation; Financial Interests, Personal, Advisory Board: Inivata; Financial Interests, Personal, Research Grant: F. Hoffmann-La Roche Ltd./Genentech, Inc.; Financial Interests, Personal, Research Grant: KailosGenetics; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: BMS; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Lilly; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: F. Hoffmann-La Roche Ltd./Genentech, Inc.; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Daiichi-Sankyo; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Caris Life Sciences; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. A. Tan: Non-Financial Interests, Institutional, Research Grant: Genentech/Roche; Non-Financial Interests, Institutional, Research Grant: Pfizer; Non-Financial Interests, Institutional, Research Grant: Merck; Non-Financial Interests, Institutional, Research Grant: Tesaro; Financial Interests, Personal, Advisory Board: Genentech; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Immunomedics; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: AbbVie; Financial Interests, Personal, Advisory Board: Athenex; Financial Interests, Personal, Advisory Board: G1 Therapeutics; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Advisory Board: Merck; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. L. Gianni: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: ADC Therapeutics; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: Eli Lilly; Financial Interests, Personal, Advisory Board: G1 Therapeutics; Financial Interests, Personal, Advisory Board: Genentech, Inc.; Financial Interests, Personal, Advisory Board: Genomic Health; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Oncolytics Biotech; Financial Interests, Personal, Advisory Board: Odonate Therapeutics; Financial Interests, Personal, Advisory Board: Onkaido Therapeutics; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Taiho Pharmaceutical; Financial Interests, Personal, Advisory Board: Sandoz; Financial Interests, Personal, Advisory Board: Seattle Genetics; Financial Interests, Personal, Advisory Board: Synthon and Zymeworks; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: Zymeworks; Financial Interests, Institutional, Research Grant: Revolution Medicines; Financial Interests, Personal, Advisory Role: Forty Seven; Financial Interests, Personal, Advisory Role: Metis Precision Medicine; Financial Interests, Personal, Advisory Role: Menarini Ricerche; Financial Interests, Personal, Advisory Role: Synaffix; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Revolution Medicines; Non-Financial Interests, Personal, Other, Patent; EPA 12195182.6 12196177.5-Roche, pending (coinventor): Roche; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. S. Kmmel: Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Genomic Health; Financial Interests, Personal, Advisory Role: Exact Science; Financial Interests, Personal, Advisory Role: Seagen; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Advisory Role: Celgene; Financial Interests, Personal, Advisory Role: Daiichi Sanyko; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Somatex; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: PFM medical; Financial Interests, Personal, Advisory Role: Lily; Non-Financial Interests, Personal, Other: Roche; Non-Financial Interests, Personal, Other: Daiichi Sankyo; Non-Financial Interests, Personal, Other: Lily; Non-Financial Interests, Personal, Other: Sonoscape; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. C. Dang: Financial Interests, Personal, Other, Honoraria: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Other, Honoraria: Genentech, Inc.; Financial Interests, Personal, Other, Honoraria: Daiichi-Sankyo; Financial Interests, Personal, Other, Honoraria: Lilly; Financial Interests, Personal, Other, Honoraria: Puma Biotechnology; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. A. Schneeweiss: Financial Interests, Institutional, Research Grant: Celgene; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: AbbVie; Financial Interests, Personal, Expert Testimony: Roche; Financial Interests, Personal, Expert Testimony: AstraZeneca; Financial Interests, Personal, Other, Travel expenses: Celgene; Financial Interests, Personal, Other, Travel expenses: Roche; Financial Interests, Personal, Other, Honoraria: Roche; Financial Interests, Personal, Other, Honoraria: Celgene; Financial Interests, Personal, Other, Honoraria: Pfizer; Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Other, Honoraria: Novartis; Financial Interests, Personal, Other, Honoraria: MSD; Financial Interests, Personal, Other, Honoraria: Tesaro; Financial Interests, Personal, Other, Honoraria: Lily; Financial Interests, Personal, Other, Travel expenses: Pfizer; Financial Interests, Personal, Other, Honoraria: Seagen; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. J. O'Shaughnessy: Financial Interests, Personal, Advisory Role: AbbVie; Financial Interests, Personal, Advisory Role: Agendia; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Celgene; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Personal, Advisory Role: Genentech, Inc.; Financial Interests, Personal, Advisory Role: Immunomedics; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Lilly; Financial Interests, Personal, Advisory Role: Merck; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Odonate; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Puma; Financial Interests, Personal, Advisory Role: Prime Oncology; Financial Interests, Personal, Advisory Role: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Advisory Role: Seattle Genetics; Financial Interests, Personal, Advisory Role: Daiichi Sankyo; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. H. Liu: Financial Interests, Personal, Full or part-time Employment: Genentech; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. C. Aguila: Financial Interests, Personal, Full or part-time Employment, Clinical Scientist/Medical Director: F. Hoffmann-La Roche Ltd.; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. S. Heeson: Financial Interests, Personal, Full or part-time Employment: Roche Products Ltd.; Financial Interests, Personal, Stocks/Shares: Roche Products Ltd.; Non-Financial Interests, Personal, Other, Patent; PH FDC SC: Roche; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. H. Macharia: Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Full or part-time Employment: F. Hoffman-La Roche. Cancer 15, 1318. Management of toxicities from immunotherapy: ESMO Clinical Practice Interactive/Pocket Guideline Interactive/Pocket Guideline Constipation in Advanced Cancer 1 2 3 Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem?
Subfloor Thickness For Shower Pan,
Black Uhlans Albury,
Articles E
esmo 2017 hypersensitivity